



असर्फी हॉस्पिटल

सबके लिए स्वास्थ्य

AHL/AO/2026/1340

Date: 07 August 2026

To

The Listing Department
BSE Limited
25th Floor, Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Sub: Submission of Investor Presentation for the Quarter Ended 30 June 2026.

Ref: Scrip Code: 543943

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the Investor Presentation of Asarfi Hospital Limited for the quarter ended **30 June 2026**.

The aforesaid Investor Presentation is also being made available on the Company's website at www.asarfi.in.

Kindly take the above information on record and bring the same to the notice of all concerned.

Thanking you.

Yours faithfully,

For Asarfi Hospital Limited

UDAI PRATAP SINGH
(Udai Pratap Singh)
Managing Director
DIN: 08453794



Asarfi Hospital Limited

Baramuri, P.O.: B Polytechnic, Dhanbad 828 130 || CIN: L85110JH2005PLC011673
Branch Office: Khatal Road, Dhaiya, ISM, Dhanbad 826004 || www.asarfihospital.com
Phone: 7808368888, 9234302735 || Email: info@asarfihospital.com



20+
Years

Trust | Quality | Care



Leading Healthcare Provider in Eastern India

Investor Presentation

Q1'FY27




Disclaimer



Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performance and are subject to various known and unknown risks, uncertainties, and assumptions that are inherently difficult to predict. These risks and uncertainties encompass, but are not limited to, the performance of the economy, industry trends, competitive landscape, the company's ability to successfully execute its strategy, technological advancements, changes in market preferences, and exposure to market risks, as well as other potential risks. The company's actual results, levels of activity, performance, or achievements may differ materially and adversely from the results expressed or implied in this presentation. The company assumes no obligation to update any forward-looking information contained in this presentation. Any forward-looking statements and projections made by third parties included in this presentation are not endorsed or adopted by the company, and the company disclaims any responsibility for such third-party statements and projections. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the current views and assumptions of the Company's management regarding future events.

Q1'FY27 Highlights

Quarterly Snapshot – Q1'FY27 (YoY)



* Occupancy is based on effective beds occupied during the period.

** Financials are on Consolidated basis.

Quarterly Profit and Loss Summary




Standalone						Consolidated					
(₹ in Lakhs)						(₹ in Lakhs)					
Particulars	Q1'FY26*	Q4'FY26	Q1'FY27	QoQ %	YoY%	Particulars	Q1'FY26*	Q4'FY26	Q1'FY27	QoQ %	YoY%
Revenue from operations	3,566	4,503	4,734	5.1%	32.8%	Revenue from operations	3,568	4,524	4,753	5.1%	33.2%
Material costs	(857)	(987)	(1,084)	9.8%	26.4%	Material costs	(857)	(987)	(1,084)	9.8%	26.4%
Employee benefit expenses	(578)	(686)	(786)	14.6%	36.0%	Employee benefit expenses	(580)	(705)	(796)	12.9%	37.1%
Other expenses	(1,428)	(2,045)	(1,922)	-6.0%	34.7%	Other expenses	(1,431)	(2,060)	(1,928)	-6.4%	34.7%
EBITDA	703	786	942	19.9%	33.9%	EBITDA	699	772	946	22.5%	35.3%
EBITDA Margin %	19.7%	17.4%	19.9%			EBITDA Margin %	19.6%	17.1%	19.9%		
Depreciation and Amortization	(296)	(274)	(313)	14.3%	5.9%	Depreciation and Amortization	(299)	(276)	(315)	14.2%	5.3%
Other Income	142	67	59	-10.9%	-58.2%	Other Income	142	64	57	-11.8%	-60.0%
EBIT	549	578	688	19.0%	25.3%	EBIT	541	560	688	22.7%	27.0%
EBIT Margin %	15.4%	12.8%	14.5%			EBIT Margin %	15.2%	12.4%	14.5%		
Finance costs	(122)	(71)	(117)	65.8%	-4.1%	Finance costs	(122)	(71)	(117)	65.8%	-4.1%
EBT	427	507	571	12.5%	33.6%	EBT	420	490	571	16.5%	36.0%
Taxes	(108)	(98)	(144)	46.7%	33.9%	Taxes	(108)	(98)	(144)	46.7%	33.9%
PAT	320	409	427	4.3%	33.5%	PAT	312	392	427	8.9%	36.7%
PAT Margin %	9.0%	9.1%	9.0%			PAT Margin %	8.7%	8.7%	9.0%		

* Q1'FY26 figures have been restated/reclassified wherever necessary to conform to the current year's presentation and classification of the financial statements.


Quarterly Highlights – Q1'FY27



Financials (Standalone):



IPD-OPD Revenues (₹ in lakhs):



31%
YoY Growth in IPD Revenues

Super-Specialty Hospital

ARPOB
23,498
in Q1'FY27
(vs ₹19,398 in Q1'FY26)


Occupancy Rate
59%
in Q1'FY27
(vs 64% in Q1'FY26)

Cancer Hospital


ARPOB
₹31,892
in Q4'FY26
(vs ₹31,198 in Q1'FY26)

Occupancy Rate
56%
in Q1'FY27
(vs 42% in Q1'FY26)

Department-wise Revenue Mix Q1'FY27:




- Cardiology
- General Medicine
- Neurosciences
- General Surgery
- Paediatrics and Neonatology
- Orthopaedics
- Obstetrics and Gynaecology
- Gastroenterology
- Others*




- Medical Oncology
- Surgical Oncology
- Radiation Oncology
- Others*

Key Financial Parameters Over The Period - Standalone


Revenue (₹ in Lakhs)




EBITDA (₹ in Lakhs) and Margin %



EBIT (₹ in Lakhs) and Margin %




PAT (₹ in Lakhs) and Margin %




Key Financial Parameters Over The Period - Consolidated


Revenue (₹ in Lakhs)




EBITDA (₹ in Lakhs) and Margin %



EBIT (₹ in Lakhs) and Margin %





PAT (₹ in Lakhs) and Margin %




Revenue Mix – Q1'FY27 vs Q1'FY26



Super-Specialty Hospital Unit



Q1'FY27 YoY Revenue Growth % by Specialty



Revenue Contribution by
Top 3 Specialties

52% (vs 60% in Q1'FY26)



YoY Revenue Growth of
Top 3 Specialties

55%



Growth Drivers

The YoY growth in **Neurosciences, Paediatrics & Neonatology, Orthopaedics, Obstetrics & Gynaecology, and Gastroenterology** was driven by:


- Higher patient volumes and higher surgical activity.
- Higher OPD-to-IPD conversion.
- Expanded consultant services and better OT utilization.

*Others Include: Department of Pulmonology, Urology, Nephrology, ENT, Emergency, Oncology, PHC, Dental Science, Plastic Surgery, Physiotherapy, Ophthalmology, Anaesthesiology, Nutrition & Dietetics and Liver transplant.


Revenue Mix – Q1'FY27 vs Q1'FY26



Cancer Hospital Unit




■ Medical Oncology
■ Surgical Oncology
■ Radiation Oncology
■ Others*



■ Medical Oncology
■ Surgical Oncology
■ Radiation Oncology
■ Others*

Q1'FY27 YoY Revenue Growth % by Specialty



Revenue Contribution by Top 3 Specialties

77% (vs 88% in Q1'FY26)



YoY Revenue Growth of Top 3 Specialties

28%





Reasons for Movement in Revenue Streams

- The YoY decline in Surgical Oncology revenue was driven by lower complex surgery volumes and lower case realizations.
- The YoY growth in revenue from other departments was primarily driven by higher referrals, expanded oncology services, and increased follow-up treatment cycles.

*Others Include: Head and Neck oncology, Haemato-oncology and Nuclear Medicine.

IPD-OPD Highlights (Both Hospital Units)



8.2%
QoQ Growth in Q1'FY27 Patient Volume




7.3%
YoY Growth in Q1'FY27 IPD Revenue



4.23 Days ALOS | **4.24 Days ALOS**
Super-Specialty Unit | Cancer Hospital Unit

Unit-wise ARPOB, Bed Capacity and Occupancy %



Reasons for decrease in ARPOB (Q1'FY27 vs Q4'FY26) in Super-Specialty Unit:

- Addition of 20 critical care beds, resulting in temporary ARPOB dilution.

Reasons for increase in Occupancy % (Q1'FY27 vs Q4'FY26) in Both Unit:


- Driven by stronger marketing and referral outreach, alongside greater healthcare awareness, elevating patient admissions.

Reasons for increase in ARPOB (Q1'FY27 vs Q4'FY26) in Cancer Unit:

- Driven by higher patient volumes and stronger revenue contribution from Medical Oncology and Radiation Oncology departments.

* During Q1'FY27, Total bed capacity across both the hospital units was at 350 out of which Effective beds were at 297. Further, occupancy % has been calculated on the basis of effective beds.

Surgery Count



Quarterly Updates

Key Quarterly Updates



- Asarfi Cancer Institute hosted the two-day **Cancer Conclave 2026** (27–28 June 2026) at Dhanbad, themed "**Prevention to Cure**," bringing together **200+ oncologists** from AIIMS Deoghar, HCG Ranchi, CNCI Kolkata, and other leading institutions to discuss early detection and advances in cancer care. The event strengthened AHL's physician outreach and reinforced its commitment to comprehensive cancer care.



Asarfi Hospital conducted a CME on "**Basics of Oncology and Role of Radiotherapy in Cancer Management**" and "**Thrombocytopenia Management in Real World**" on **25 April 2026** in **Koderma**. The program supported AHL's district-level physician outreach strategy by strengthening clinical engagement and referral networks.



- Asarfi Hospital strengthened its business generation through a hoarding campaign, digital promotion, and expansion into **Godda, Sahibganj, and Pakur**, enhancing patient outreach and reinforcing its regional presence beyond Dhanbad.



- Asarfi Hospital **strengthened** its **referral-driven growth** strategy by onboarding new doctors and nursing home owners, expanding its referral network and improving patient acquisition across nearby markets.

* Actual photos.

Asarfi Hospital At A Glance

* Actual photo of Asarfi Hospital.

Asarfi Hospital: Leading Healthcare Player In Jharkhand



Healthcare Excellence Since 2005

- Serving Dhanbad and neighboring areas for 20+ years with affordable, best-in-class healthcare facilities. Operating two hospitals with 350 total beds across Super-Specialty and Cancer Care Units.
- The Super-Specialty hospital is the first and only in Dhanbad region with 23+ specialized facilities, offering advanced and comprehensive critical care, emergency care, cardiac care, diagnostics and other multi-specialty services all under one roof.
- In 2024, Asarfi Cancer Institute was established which is now the first dedicated comprehensive cancer care hospital and just 1 out of 3 cancer hospital in the state of Jharkhand.



Expert Medical Team

- 103+ doctors including 70 full-time in-house doctors and remaining visiting doctors.
- 1,580+ nursing staff and support staff.



20+ Years of Experience



Trusted Healthcare Partner

- Empaneled with Govt of Jharkhand for Mukhyamantri Gambhir Bimari Upchar Yojana (MGBUY), East Central Railway, Coal India Ltd, Leading TPAs and many other reputed Govt agencies.

Journey Over The Years



2005-2009: Foundation

- **2005:** Asarfi Hospital was incorporated in Dhanbad
- **2008:** Started IPD Department
- **2009:** Established Burn Department



2016-2024: Expansion and IPO



- **2016:** Completed Expansion of Block-A and increased Bed capacity to 120 Beds
- **2017:** Established Cardiac department and started construction of Block-B
- **2019:** Land allocated for Cancer Hospital and started construction of Block-C
- **2022:** Started construction of Cancer Hospital
- **2023:** Raised ₹26.94 Cr through IPO and listed on BSE-SME platform
- **2024:** Operationalised the new Cancer Hospital in Ranguni with initial capacity of 50 beds – Just 1/3 in Jharkhand



2025-2026 and Beyond: Partnerships and Tech Upgradation

- **2025:** Signed MoU with Gleneagles Hospital, Chennai to set up Jharkhand's 1st Multi-Organ Transplant Unit
- **2026:** Upgraded Cath Lab with the advanced Philips Azurion 5 M12 Image Guided Therapy System to enhance interventional cardiology and cardiac care capabilities
- **2026:** Installed GE Healthcare Dual-Detector SPECT Gamma Camera at Asarfi Cancer Institute to strengthen nuclear medicine diagnostics and therapeutic services

Our Departments

 Cardiology	 Neurosciences	 General medicine	 Paediatrics & Neonatology	 Obstetrics & Gynaecology	 General Surgery
 Gastroenterology	 Orthopaedics	 Burn & Plastic Surgery	 Oncology	 Nephrology	 Urology
 Ophthalmology	 ENT	 Day Care services	 Dental Sciences	 Physiotherapy	 Emergency
 Nutrition & Dietetics	 Anaesthesiology & Critical Care	 Radiology	 Pulmonology	 Pain Management	 PHC



* Actual photo of Asarfi Hospital.

Backed By Cutting-Edge Infrastructure and Facilities



Asarfi Hospital, Dhanbad



285 Beds | ₹23,498 ARPOB |
59% Occupancy | ALOS 4.2 Days

- Established in 2005
- Specialty in Cardiology, General Medicine and Neurology (~52% Revenues)
- Facilities: Full-fledged High Dependency Unit, Emergency Department, Outpatient consultation, CCU, ICU, NICU, SICU and Labor Room

Asarfi Cancer Institute, Dhanbad



65 Beds | ₹31,892 ARPOB |
56% Occupancy | ALOS 4.2 Days

- Established in 2024
- Specialty in Preventive Oncology, Medical Oncology, Surgical Oncology, Radiation Oncology, Day Care Chemotherapy, Nuclear Medicine and Pain Management
- USP: Just 1 out of 3 cancer hospitals in the state of Jharkhand



Varian Tru Beam



Philips Azurion 5 M12
Image-Guided Therapy System



GE Dual Detector SPECT
Gamma Camera


- Jharkhand's 1st and most Advanced Radiation Machine the "Varian Tru Beam", delivering precision cancer care, advance imaging & tracking and faster treatment delivery.
- Investment in GE Healthcare's Dual-Detector SPECT Gamma Camera (nuclear imaging systems) positions Asarfi Cancer Institute among the first hospitals with this technology in the entire state of Jharkhand and strengthens it as a comprehensive cancer care facility.
- Upgrading existing Cath Lab with the Philips Azurion 5 M12 Image-Guided Therapy System, with addition of IVUS capability, enabling interventional teams to perform challenging cardiac interventions.

Delivering Consistent Shareholder Returns



Share Price History

Asarfi Hospital Limited is planning to migrate from BSE SME to Main Board, subject to regulatory requirements and approvals.




* Market Cap data is of 30th July, 2026.

Stock Info

BSE Scrip Code	SME: 543943
Shares Outstanding	1,96,77,300
52-Week Range (INR)	117 - 257
Free Float (%)	38.83%
Market Cap (INR Cr)*	425
FY26 EPS (INR)	8.47
Net D/E (June 2026)	0.46
ROCE (June 2026)	17.06%
P/E (x) (TTM)	23.87
P/BV (x) (June 2026)	4.17
PEG Ratio (x)	0.78
EV/Revenue (x) (TTM)	2.57
EV/EBITDA (x) (TTM)	13.05

Shareholding Structure (as of June 2026)



Competitive Strengths



30 Lakh+

Population Served

1 out of 3

Cancer Hospital
in Jharkhand

103+

Medical
Professionals

Concentric Impact



Regional dominance creates a defensible geographic moat



Regional Advantage

- Eastern India's healthcare market offers a compelling growth opportunity, underpinned by low penetration of organized hospital chains, high population density, and rising health insurance adoption.
- Strong oncology positioning with presence as 1 of only 3 cancer hospitals in Jharkhand, enabling regional referral dominance and high-value case mix.
- Limited healthcare infrastructure & low bed density, leading to structural supply-demand gap and reduced competitive intensity versus metro markets.



Technology Leadership

- Equipped with Jharkhand's first and most advanced Linear Accelerator radiation machine- The Varian True Beam, GE's Dual Detector SPECT Gamma Camera and Philips Azurion 5 M12 Image-Guided Therapy System.



Financial and Operational Stability

- Consistent operational and financial performance with strong revenue growth, healthy operating margins, increasing profits and stable capital structure.

Leadership Team



Harendra Singh

Promoter & CFO

- A visionary entrepreneur inspired by the Company's Purpose—Health for All.
- Believes that good leaders must be passionate about learning and are focused to develop world-class organizations.
- Holds Bachelor of Science degree in Electronics from AN College, Patna and MBA from LBSIM, New Delhi.



Udai Pratap Singh

Promoter & MD

- Started his career in 2017, he is a process and system driven person and believes strongly in "quality" and "efficiency" in healthcare.
- Graduated from PES Institute of Technology and pursued his master's degree from University of Cincinnati, USA.



Sukanti Kumar Das

Non-Executive Director

- Renowned Consultant Gynaecologist with over 35 years of experience.
- Previously, the Deputy CMO in Central Hospital, Dhanbad and the Chairman of FOGSI at Dhanbad, Jharkhand.
- Graduated from R.G. Kar Medical College in Calcutta and completed DGO, MD from PGI Chandigarh.



Madhuri Singh

Executive Director

- Directs the Quality, Housekeeping and Diet & Nutrition for the hospital.
- She has excellent cleanliness skills and is experienced in the field for over 10 years.
- Innovation, quality, and exclusivity are her guiding principles.



Gopal Singh

Executive Director

- Experienced individual with a strong background in civil construction and procurement.
- Facilitates seamless collaboration between cross-functional teams.

Thank You

Contact Details:

Mr. Udai Pratap Singh

Managing Director (MD)

Contact No. - 9608833708

Email Id - cs@asarfihospital.com

ASARFI HOSPITAL LIMITED | Baramuri, B Polytechnic, Dhanbad, Jharkhand 828130 | CIN - L85110JH2005PLC011673 | cs@asarfihospital.com | www.asarfi.in